Endogenous opioids and addiction to alcohol and other drugs of abuse

Current Topics in Medicinal Chemistry

Volumn 9, Issue 11, 2009, Pages 999-1015

  Gianoulakis, Christina ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; ACAMPROSATE; ALCOHOL; AMPHETAMINE DERIVATIVE; BETA ENDORPHIN; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COCAINE; DELTA OPIATE RECEPTOR; DOPAMINE; DYNORPHIN; KAPPA OPIATE RECEPTOR; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; NALTREXONE; NALTRINDOLE; NICOTINE; PRODYNORPHIN; PROENKEPHALIN; PROOPIOMELANOCORTIN; OPIATE PEPTIDE;

ALCOHOLISM; BEHAVIOR; BINDING AFFINITY; BRAIN REGION; CIGARETTE SMOKING; COCAINE DEPENDENCE; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG ABUSE; DRUG EFFICACY; FEEDING BEHAVIOR; GABAERGIC SYSTEM; HEREDITY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PATIENT COMPLIANCE; PEPTIDE SYNTHESIS; PROTEIN FUNCTION; RECEPTOR BINDING; REINFORCEMENT; REVIEW; REWARD; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; VENTRAL TEGMENTUM; ADDICTION; BRAIN; MOTIVATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALCOHOLISM; BRAIN; HUMANS; MOTIVATION; OPIOID PEPTIDES; SUBSTANCE-RELATED DISORDERS;

EID: 74049095598     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789630956     Document Type: Review

References (245)

1. Simon, E.; Hiller, J; Edelman, I. Stereospecific binding of the potent narcotic analgesic 3H-etorphine to rat brain homogenate. Proc. Natl. Acad. Sci. USA 1973, 70, 1947-1949.
2. Pert, C.; Snyder, S. Opiate receptor: demonstration in nervous tissue. Science 1973, 179, 1011-1014.
3. Terenius, L. Stereospecific interaction between narcotic analgesics and synaptic plasma membrane fraction of rat brain cortex. Acta Pharmacol. Toxicol. (Copenh.) 1973, 32, 317-320.
4. Mansour, A.; Khachaturian, H.; Lewis, M.E.; Akil, H.; Watson, S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 1988, 11, 308-374.
5. Akil, H.; Watson, S.J.; Young, E.; Lewis, M.E.; Khachaturian, H.; Walker, J.M. Endogenous opioids: biology and function. In Cowan, W.M. Ed., Annual Review of Neuroscience. Annual Review Palo Alto 1984, 7, 223-255.
6. Van Ree, J.M.; De Wied, D.; Bradbury, A.F.; Hulme, E.C.; Smyth, D.C.; Snell, C.R. Induction of tolerance to the analgesic action of lipotropin C-fragment. Nature 1976, 264, 792-794.
7. Wei, E.; Loh, H. Physical dependence of opiate-like peptides. Science 1976, 193, 1262-1263.
8. Belluzzi, J.D.; Stein L. Enkephalin may mediate euphoria and drive-reduction reward. Nature 1977, 266, 556-558.
9. Van Ree, J.M. Reinforcing stimulus properties of drugs. Neuropharmacology 1979, 18, 963-969.
10. Wise, R.A. Drug-activation of brain reward pathways. Drug Alcohol Depend. 1998, 51, 13-22.
11. Terenius, L.; Wahlstrom, A. Inhibitor(s) of narcotic receptor binding in brain extracts and cerebrospinal fluid. Acta Pharmacol. 1974, 35 (suppl. 1), 15.
12. Hughes, J.; Smith, T.W.; Kosterlitz, H.W.; Fothergill, L.A.; Morgan, B.A.; Morris, H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258, 577-579.
13. Bradbury, A.F.; Smyth, D.G.; Snell, C.R.; Birdsall, N.J.M.; Hulme, E.C. C-fragment of lipotropin has a high affinity for brain opiate receptors. Nature 1976, 260, 793-795.
14. Loh, H.; Tseng L.F.; Wei, E.; Li, C.H. β-endorphin is a potent analgesic agent. Proc. Nat. acad. Sci. USA 1976, 73, 2895.
15. Goldstein, A.; Tachibana, S.; Lowney L.I.; Hunkapiller, M; Hood L. Dynorphin (1-13), an extraordinary potent opioid peptide. Proc. Nat. Acad. Sci. USA 1979, 76, 6666-6670.
16. Khachaturian. H.; Lewis, M.E.; Schafer, M.K.H.; Watson, S.J. Anatomy of the CNS opioid systems. Trends Neurol. Sci. 1985, 10, 111-119.
17. Nakanishi, S.; Inoue, A.; Kita, T.; Nakamura, M.; Chang, A.C.; Cohen, S.N.; Numa, S. Nucleotide sequence of clones cDNA for bovine corticotropin-beta-lipotropin precursor. Nature 1979, 278, 423.
18. Comb, M.; Seeburg, P.H.; Adelman, J.; Eiden , L.; Herbert,E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 1982, 295, 663-666.
19. Kakidani, H.; Furutani, Y.; Takahashi, H.; Noda, M.; Morimoto, Y.; Hirose, T.; Asai, M.; Inayama, S.; Nakanishi, S.; Numa, S. cloning and sequence analysis of cDNA for porcine beta-neoendorphin/dynorphin precursor. Nature 1982, 298, 245-249.
20. Crine, P.; Gianoulakis, C.; Seidah, N.G.; Gossard, F.; Pezalla, P.D.; Lis, M.; Chretien, M. Biosynthesis of β-endorphin from β-lipotropin and a larger molecular weight precursor in rat pars intermedia. Proc. Natl. Acad. Sci. USA 1978, 75, 4719-4723.
21. Dores, R.M.; Jain, M.; Akil, H. Characterization of the forms of β-endorphin and α-MSH in the caudal medulla of the rat and guinea pig. Brain Res. 1986, 377, 251-260.
22. Bloom, F.E. The endorphins: A growing family of pharmacologically pertinent peptides. Ann. Rev. Pharmacol. Toxicol. 1983, 23, 151-170.
23. Handa, B.; Lane, A.; Lord.J.; Morgan, B.; Rance M.; Smith, C. Analogues of beta-LPH 61-64 processing selective agonist activity at mu opiate receptors. Eur. J. Pharmacol. 1981, 79, 531-540.
24. Mosberg, H.I.; Hurst, R.; Hruby, V.J.; Gee, K.; Yamamura, H.I.; Galligan, J.J.; Burks, T.F. Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors Proc. Natl. Acad. Sci. USA 1983, 80, 5871-5874.
25. Von Voightlander, P.; Lahti, R.; Ludens, J. U-50, 488H: a selective and structurally novel non-mu (kappa) opioid agonist. J. Pharmacol. Exp. Ther. 1983, 24, 111-115.
26. Gulya, K.; Pelton, J.; Hruby, V.; Yamamura, H. Cyclic somatosstatin octapeptide analogues with high affinity and selectivity toward mu opioid receptors. Life Sci. 1986, 30, 2221-2229.
27. Portoghese, P.; Lipowski, A.; Takemori, A. Binaltorphimine and norbinaltorphimine, potent and selective -κ-opioid receptor antagonists. Life Sci. 1987, 40, 1287-1292.
28. Portoghese, P.; Sultana, M.; Takemori, A. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur. J. Pharmacol. 1988, 146, 185-186.
29. Pasternak, G.W. Multiple morphine and enkephalin receptors: biochemical and pharmacological aspects. Ann. N.Y. Acad. Sci. 1986, 467, 130-139.
30. Negri, L.; Potenza, R.L.; Corsi, R.; Melchiorri, P. Evidence for two subtypes of δ opioid receptors in rat brain. Eur. J. Pharmacol. 1991, 196, 335-336.
31. 6] enkephalin and naltrindole 5′-isothiocyanate: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 257, 1069-1075.
32. Akil, H.; Watson, S.J. Cloning of kappa opioid receptors: functional significance and future directions. Prog. Brain Res. 1994, 100, 81-86.
33. Evans, C.J.; Keith D.E. Jr.; Morrison, H.; Magendzo, K.; Edwards, R.H. Cloning of a delta opioid receptor by functional expression. Science 1992, 258, 1952-1955.
34. Kieffer, B.; Befort, K.; Gaveriaux-Ruff, C.; Hirth, C. The delta opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Nat. Acad. Sci. USA 1992, 89, 12048-12052.
35. Yasuda, K.; Raynor, K.; Kong, H.; Breder, C.D.; Takeda, J.; Reisine, T.; Bell, G.I. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Nat. Acad. Sci. USA 1993, 90, 6736-6740.
36. Kong, H.; Raynor, K.; Yasuda, K.; Moe, S.T.; Portoghese, P.S.; Bell, G.I.; Reisine, T. A single residue, aspartic acid 95, in the delta opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 1993, 268, 23055-23058.
37. Chen, Y.; Mestek, A.; Liu, J.; Hurley J.A.; Yu, L. Molecular cloning and functional expression of a μ-opioid receptor from rat brain. Mol. Pharmacol. 1993, 44, 8-12.
38. Wang, J.B.; Imai, Y.; Eppler, C.M.; Gregor, P.; Spivak, C.E.; Uhl, G.R. μ opiate receptor: cDNA cloning and expression. Proc. Natl. Acad. Sci. USA 1993, 90, 10230-10234.
39. Thompson, R.C.; Mansour, A.; Akil, H.; Watson, S.J. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 1993, 11, 903-913.
40. Meng, F.; Xie, G.X.; Thompson, R.C.; Mansour, A.; Goldstein, A.; Watson, S.J.; Akil, H. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc. Natl. Acad. Sci. USA 1993, 90, 9954-9958.
41. Minami, M.; Toya, T.; Katao, Y.; Maekawa, K.; Nakamura, S.; Onogi, T.; Kaneko, S.; Satoh, M. Cloning and expression of a cDNA for the rat κ-opioid receptor. FEBS Lett. 1993, 329, 291-295.
42. Yasuda, K.; Espinosa III, R.; Takeda, J.; Le Beau, M.M.; Bell, G.I. Localization of the kappa opioid receptor gene to human chromosome band 8q11.2. Genomics 1994, 19, 596-597.
43. Akil, H.; Owens, C.; Gutstein, H.; Taylor, L.; Curran, E.; Watson, S. Endogenous opioids: overview and current issues. Drug Alcohol Depend. 1998, 51, 127-140.
44. Charnes, M.E. Ethanol and opioid receptor signalling. Experientia 1989, 45, 518-528.
45. Olson, G.A.; Olson, R.D.; Kastin, A.B. Endogenous Opioids (review). Peptides 1990, 11, 1277-1304.
46. Koob, G.F. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 1992, 13, 177-193.
47. Zadina, J.E.; Hackler, L.; Ge, L.-J.; Kastin, A.J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1997, 386, 499-502.
48. Chick, J.; Erickson, C. Conference Summary: Consensus Conference on alcohol dependence and the role of pharmacotherapy in its treatment. Alcohol. Clin. Exp. Res. 1996, 20, 391-402.
49. Spanagel, R.; Weiss, F. The dopamine hypothesis of reward: past and current status. Trends Neurol. Sci. 1999, 22, 521-527.
50. Heyser, C.J.; Roberts, A.J.; Schulteis, G.; Koob, G.F. Central administration of an opioid antagonist decreases oral ethanol self-administration in rats. Alcohol Clin. Exp. Res. 1999, 23, 1468-1476.
51. June, H.L.; Cummings, R.; Eiler, W.J.A.I.; Foster, K.L.; McKay, P.F.; Seyoum, R.; Garcia, M.; McCane, S.; Grey, C.; Hawkins, S.E.; Mason, D. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol-and saccharin-reinforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology 2004, 29, 285-299.
52. Bechtholt, A.J.; Cunningham, C.L. Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. Behav. Neurosci. 2005, 119, 213-23.
53. Zahm, D.S.; Heimer, L. Ventral striatolpallidal parts of the basal ganglia in the rat: I. Neurochemical compartmentation as reflected by the distributions of neurotensin and substance P immunoreactivity. J. Comp. Neurol. 1988, 272, 516-535.
54. Heimer, L.; Zahm, D.S.; Churchill, L., Kalivas, P.W.; Wohltmann, C. Specificity in the projection patterns of accumbal core and shell in the rat. Neuroscience 1991, 41, 89-125.
55. Curran, E.J.; Watson, S.J. Dopamine receptor mRNA expression patterns by opioid peptide cells in the nucleus accumbens of the rat: a double in situ hybridization study. J. Comp. Neurol. 1995, 361, 57-76.
56. Mansour, A.; Fox, C.A.; Meng, F.; Akil, H.; Watson, S.J. Kappa1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Cell Mol. Neurosci. 1994, 5, 124-144.
57. Mansour, A.; Fox, C.A.; Thompson, R.C.; Akil, H.; Watson, S.J. Mu-opioid receptor mRNA expression in the rat CNS: comparison to mu-receptor binding. Brain Res. 1994, 643, 245-265.
58. Devine, D.P.; Wise, R.A. Self administration of morphine, DAMGO and DPDPE into the ventral tegmental area of rats. J. Neurosci. 1994, 14, 1978-1984.
59. Cooper, S.J. Interactions between endogenous opioids and dopamine: Implications for reward and aversion. In: Willner, P.; Scheel-Kruger, J. Eds., The mesolimbic dopamine system: from motivation to action. John Wiley, England, 1991, pp. 331-366.
60. Shippenberg, T.S.; Herz, A.; Spanagel, R.; Bals-Kubik, R.; Stein, C. Conditioning of opioid reinforcement: neuroanatomical and neurochemical substrates. Ann. N.Y. Acad. Sci. 1992, 654, 347-356.
61. Chesselet, M.; Cheramy, A.; Reisine, T.; Lubetzki, C.; Desban, M.; Glowinski, J. Local and distal effects induced by unilateral striatal application of opiates in the absence or in the presence of naloxone on the release of dopamine in both caudate nuclei and substantiae nigrae of the cat. Brain Res. 1983, 258, 229-242.
62. Di Chiara, G.; Imperato, A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 1988, 244, 1067-1080.
63. Devine, D.P.; Leone, P.; Pocock, D.; Wise, R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 1993, 266, 1236-1246.
64. Mulder, A.; Burger, D.; Wardeh, G.; Hogenboom, F.; Frankhuyzen, A. Pharmacological profile of various kappa-agonists at kappa-, mu- and delta-opioid receptors mediating presynaptic inhibition of neurotransmitter release in the rat brain. Br. J. Pharmacol. 1991, 102, 518-522.
65. Mulder, A.; Schoffelmeer, A. Multiple Opioid Receptors and Presynaptic Modulation of Neurotransmitter Release in the Brain. In: Herz, A. Ed., Opioids. I. Springer-Verlag, Berlin, 1993, pp. 125-144,
66. Marks, M.J.; Stitzel, J.A.; Romm, E., Wehner, J.M.; Collins, A.C. Nicotinic binding sites in rat and mouse brain: comparison of acetylcholine, nicotine, and α-bungarotoxine. Mol. Pharmacol. 1986, 30, 427-436.
67. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258, 1946-1949.
68. Snyder, S.H.; Katims, J.J.; Annau, A.; Bruns, R.F; Daly, J.W. Adenosine receptors and the behavioral actions of methylxanthines. Proc. Natl. Acad. Sci USA 1981, 78, 3260-3264.
69. 3H] dopamine in rat brain tissue slices. Biochem. Pharmacol. 1975, 24, 847-852.
70. 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J. Pharmacol. Exp. Ther. 1975, 194, 47-56.
71. Lomazzi, M.; Slesinger, P.A.; Luscher, C. Addictive drugs modulate GIRK-channel signalling by regulating RGS proteins. Trends Pahrmacol. Sci. 2008, 29, 544-549.
72. Aryal, P.; Dvir, H.; Slesinger, P.A. A discrete alcohol pocket in GIRK channel activation. Nat. Neurosci. 2009, 12(8): 988-995.
73. Mihic, S.J.; Ye, Q.; Wick, M.J.; Koltchine, VV.; Krasowski, M.D.; Finn, S.E.; Mascia, M.P.; Valenzuela, C.F.; Hanson, K.K.; Greenblatt, E.P.; Harris, R.A.; Harrison, N.L. Sites of alcohol and volatile anaesthetic action on GABA (A) and glycine receptors. Nature 1997, 389, 385-389.
74. Kohl, R.R.; Katner. J.S.; Chernet E, McBride WJ. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopahrmacology 1998, 139,79-85.
75. Gonzales, R.A.; Weiss, F. Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J. Neurosci. 1998, 18, 10663-10671.
76. Rasmussen, D.D.; Bryant, C.A.; Boldt, B.M.; Colasurdo, E.A.; Levin, N.; Wilkinson, C.W.; Acute alcohol effects on opiomelanocortinergic regulation. Alcohol. Clin. Exp. Res. 1998, 22, 789-801.
77. Gianoulakis, C.; Barcomb. A. Effect of acute ethanol in vivo and in vitro on the β-endorphin system in the rat. Life Sci. 1987, 40, 19-28.
78. Thiagarajan, A.B., Mefford, I.N.; Eskay, R.L. Single-dose ethanol administration activates the hypothalamic -pituitary-adrenal axis; exploration of the mechanism of action. Neuroendocrinology 1989, 50, 427-432.
79. de Waele, J.-P.; Papachristou, D.; Gianoulakis, C. The alcohol preferring- C57BL/6 mice present an enhanced sensitivity of the hypothalamic β-endorphin system to ethanol than the alcohol avoiding DBA/2 mice. J. Pharmacol. Exp. Ther. 1992, 261, 788-794.
80. Keith, L.D.; Crabbe, J.C.; Robertson, L.M.; Kendall, J.W.; Ethanol stimulated endorphin and corticotropin secretion in vitro. Brain Res. 1986, 367, 222-229.
81. Gianoulakis, C. Characterization of the effect of acute ethanol administration on the release of β-endorphin peptides by the rat hypothalamus. Eur. J. Pharmacol. 1990, 180, 21-29.
82. de Waele, J.-P.; Gianoulakis, C. Effects of single and repeated exposure to ethanol on hypothalamic β-endorphin and CRH release by the C57BL/6 and DBA/2 strains of mice. Neuroendocrinology 1993, 57, 700-709.
83. Gianoulakis, C.; L'Abbee, D.; Moronval, D. Direct evidence of a biphasic effect of ethanol on the pituitary and hypothalamic β-endorphin release. In: Cros, J.; Meunier, J.-C.; Hamon, M. Eds. Advances in the Biosciences; Oxford Pergamon Press 1989, Vol. 75, pp. 527-530.
84. Boyadjieva, N.I.; and Sarkar, D.K. Effects of ethanol on basal and prostaglandin E1-induced increases in beta-endorphin release and intracellular cAMP levels in hypothalamic cells. Alcohol Clin. Exp. Res. 1997, 21, 1005-1009.
85. Olive, M.F.; Koenig, H.N.; Nannini, M.A.; Hodge, C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J. Neurosci. 2001, 21, RC184.
86. Marinelli, P.W.; Quirion, R.; Gianoulakis, C. A microdialysis profile of beta- endorphin and catecholamines in the rat nucleus accumbens following alcohol administration. Psychopharmacology 2003, 169, 60-67.
87. Bals-Kubic, R.; Ableitner, A.; Herz, A.; Shippenberg, T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 1993, 264, 489-495.
88. Jarjour, S.; Bai, L.; Gianoulakis, C. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol. Clin. Exp. Res. 2009, 33, 1033-1043.
89. Mocsary, Z.; Bradberry, C.W. Effect of ethanol on extracellular dopamine in nucleus accumbens: comparison between Lewis and Fischer 344 rat strains. Brain Res. 1996, 706, 194-198.
90. Tizabi, Y.; Copeland, R.L. Jr.; Louis, V.A.; Taylor, R.E. Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol. Clin. Exp. Res. 2002, 26, 394-399.
91. Di Chiara, G.; Imperato, A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely-moving rats. Eur. J. Pharmacol. 1985, 115, 131-132.
92. Chefer, V.I.; Czyzyk, T.; Bolan, E.A.; Moron, J.; Pintar, J.E.; Shippenberg, T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. J. Neurosci. 2005, 25, 5029-5037.
93. Dalman, F.C.; O'Malley, K.L. Kappa-opioid tolerance and dependence in cultures of dopaminergic midbrain neurons. J. Neurosci. 1999, 19, 5750-5757.
94. Ford, C.P.; Mark, G.P.; Williams, J.T. Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J. Neurosci. 2006, 26, 2788-2797.
95. Yoshida, M.; Yokoo, H.; Tanaka, T.; Mizoguchi, K.; Emoto, H.; Ishii, H.; Tanaka, M. Facilitatory modulation of mesolimbic dopamine neuronal activity by a mu-opioid agonist and nicotine as examined with in vivo microdialysis. Brain Res. 1993, 624, 277-280.
96. Gessa, G.L.; Muntoni, F.; Collu, M.; Vargiu, L.; Mereu, G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 1985, 348, 201-203.
97. Imperato, A.; DiChiara, G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J. Pharmacol. Exp. Ther. 1986, 239, 219-228.
98. Lam, M.P.; Marinelli, P.W.; Bai, L.; Gianoulakis, C. Effects of acute ethanol on opioid peptide release in the central amygdala: an in vivo microdialysis study. Psychopharmacology 2008, 201, 261-271.
99. Hyytia, P.; Kiianmaa, K. Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Alcohol. Clin. Exp. Res. 2001, 25, 25-33.
100. Foster, K.L.; McKay, P.F.; Seyoum, R.; Milbourme, D.; Yin W.; Sarma, P.V.; Cook, J.M.; June, H.L. GABA (A) and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviours. Neuropsychopharmacology 2004, 29, 269-284.
101. Finnegan, T.F.; Chen, S.R.; Pan, H.L. Effect of the {micro} opioid on excitatory and inhibitory synaptic inputs to periaqueductal gray-projecting neurons in the amygdala. J. Pharmacol. Exp. Ther. 2005, 312, 441-448.
102. Hyytia, P.; Koob, G.F. GABA(A) receptor antagonism in the extended amygdala decreases ethanol self administration in rats. Eur. J. Pharmacol. 1995, 283, 151-159.
103. Zangen, A.; Herzberg, U.; Vogel, Z.; Yadid, G. Nociceptive stimulus induces release of endogenous β-endorphin in the rat brain. Neuroscience 1998, 85, 659-662.
104. Marinelli, P.W.; Quirion, R.; Gianoulakis, C. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience 2004, 127, 777-784.
105. Kang, W.; Wilson, S.P.; Wilson, M.A. Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Nuropsychopharmacology 2000, 22, 77-88.
106. Lam, M.P.; Bai, L.; Gianoulakis, C. Effects of corticotrophin-releasing hormone receptor antagonists on ethanol induced β-endorphin release in the central amygdala. Alcohol Clin. Exp. Res. 2009, 33 (6 supplement) Abstract # 528, p142A.
107. Seizinger, B.R.; Bovermann, K.; Hollt, V.; Herz, A. Enhanced activity of the endorphinergic system in the anterior and neurointermediate lobe of the pituitary gland after chronic treatment with ethanol liquid diet. J. Pharmacol. Exp. Ther. 1984, 230, 455-461.
108. Gianoulakis, C.; Hutchison, W.D.; Kalant, H. Effects of ethanol treatment and withdrawal on the biosynthesis and processing of pro-opiomelanocortin by the rat neurointermediate lobe. Endocrinology 1988, 122, 817-825.
109. Wand, C.S. Differential regulation of anterior pituitary corticotrope function is observed in vivo but not in vitro in two lines of ethanol sensitive mice. Alcohol. Clin. Exp. Res. 1990, 14, 100-106.
110. Schulz, R.; Wuster, M.; Duka, T.; Herz, A. Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology 1980, 68, 221-227.
111. Adams, M.L.; Cicero, T.J. Effects of alcohol on β-endorphin and reproductive hormones in the male rat. Alcohol. Clin.Exp. Res. 1991, 15, 685-692.
112. Gianoulakis, C.; Angelogianni, P. Chronic ethanol increases proopiomelanocortin gene expression in the rat hypothalamus. Neuroendocrinology 1993, 57,106-114.
113. Seizinger, B.R.; Boverman, K.; Maysinger, D.; Hollt, V.; Herz, A. Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol. Biochem. Behav. 1983, 18, 361-369.
114. Scanlon, M.N.; Lazar-Wesley, E.; Grant, K.A.; Kunos, G. Proopiomelanocortin messenger RNA is decreased in the mediobasal hypothalamus of rats made dependent on ethanol. Alcohol. Clin. Exp. Res. 1992, 16, 1147-1151.
115. Seizinger, B.R.; Hollt, V.; Herz, A. Effect of chronic ethanol treatment on the in vitro biosynthesis of pro-opiomelanocortin and its post-translational processing to β-endorphin in the intermediate lobe of the rat pituitary. J. Neurochem. 1984, 43, 607-613.
116. Dave, J.R.; Eiden, L.E.; Karanian, J.W.; Eskay, R.L. Ethanol exposure decreases pituitary corticotropin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis and plasma β-endorphin levels in the rat. Endocrinology 1986, 118, 280-286.
117. Milton, G.V.; Erickson, C.K. Effect of ethanol and discomfort on brain met-enkephalin levels in male Sprague - Dawley rats. Alcohol. Clin. Exp. Res. 1991, 15, 327
118. Li, X.-W.; Li, T.-K.; Froehlich, J.C. Enhanced activity of the nucleus accumbens enkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res. 1998, 794, 35-47.
119. Nylander, I.; Hyytia, P.; Forsander, O.; Terenius, L. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol. Clin Exp. Res. 1994, 18, 1272-1279.
120. Marinelli, P.W.; Bai, L.; Quirion, R.; Gianoulakis, C. A microdialysis profile of met-enkephalin release in the rat nucleus accumbens following alcohol administration. Alcohol. Clin. Exp. Res. 2005, 29, 1821-1828.
121. Beadles-Bohling, A.S.; Crabbe, J.C.; Wiren, K.M. Elevated prodynorphin expression associated with ethanol withdrawal convulsions. Neurochem. Int. 2000, 37, 463-472.
122. Marinelli, P.W.; Lam, M.; Bai, L.; Quirion, R.; Gianoulakis, C. A microdialysis profile of dynorphin A(1-8) release in the rat nucleus accumbens following alcohol administration. Alcohol. Clin. Exp. Res. 2006, 30, 982-990.
123. Bals-Kubik, R.; Ableitner, A.; Herz, A.; Shippenberg T.s. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 1993, 264, 489-495.
124. Bormann, N.M.; Cunningham, C.L. Ethanol-induced conditioned place aversion in rats: effect of interstimulus interval. Pharmcol. Biochem. Behav. 1998, 59, 427-432.
125. Van der Kooy, D.; O'Shaunessy, M.; Mucha, R.F.; Kalant, H. Motivational properties of ethanol in naïve rats as studied by place conditioning. Pharmacol. Biochem. Behav. 1983, 19, 441-445.
126. Svingos, A.L.; Colago, E.E.O.; Pickel, V.M. Cellular sites for dynorphin activation of kappa-opioid receptors in the rat nucleus accumbens shell. J. Neurosci. 1999, 19, 1804-1813.
127. Hjelmstad, G.O.; Fields, H.L. Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell. J. Neurophysiol. 2001, 85, 1153-1158.
128. Spanagel, R.; Herz, A.; Shippenberg, T. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopamine pathway. Proc. Natl. Acad. Sci. USA 1992, 89, 2046-2050.
129. Marchant, N.J.; Densmore, V.S.; Osborne, P.B. Coexpression of prodynorphin and corticotrophin-releasing hormone in the rat central amygdala: evidence of two distinct endogenous opioid systems in the lateral division. J. Comp. Neurol. 2007, 504, 702-715.
130. Ogilvie, K.M.; Lee, S.; Rivier, C. Role of arginine vasopressin and corticotropin-releasing factor in mediating alcohol-induced adrenocorticotropin and vasopressin secretion in male rats bearing lesions of the paraventricular nuclei. Brain Res. 1997, 744, 83-85.
131. Criado, J.R.; Morales, M. Acute ethanol induction of c-Fos immunoreactivity in pre-pro-enkephalin expressing neurons of the central nucleus of the amygdala. Brain Res. 2000, 861, 173-177.
132. Merlo-Pich, E.; Lorang, M.; Yeganeh, M.; de Fonseca, F.R.; Raber, J.; Koob, G.F.; Weiss, F. Increase of extracellular corticotrophin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J. Neurosci. 1995, 15, 5439-5447.
133. Bals-Kubik, R.; Herz, A.; Shippenberg, T.S. Evidence that the aversive effects of opioid antagonists and kappa agonists are centrally mediated. Psychopharmacology 1989, 98, 203-206.
134. Shippenberg, T.S.; Bals-Kubik, R.; Herz, A. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. Trends Pharmacol. Sci. 1993, 265, 53-59.
135. Land, B.; Bruchas, M.; Lemos, J.; Xu, M.; Melief, E.; Chavkin, C. The dysphoric component of stress is encoded by activation of the dynorphin k-opioid system. J. Neurosci. 2008, 28, 407-414.
136. Hiller, J.M.; Angel, L.M.; Simon, E.J. Multiple opiate receptors: alcohol selectively inhibits binding to delta receptor. Science 1981, 214, 468-469.
137. Hiller, J.M.; Angel, L.M.; Simon, E.J. Characterization of the selective inhibition of the delta subclass of opioid binding sites by alcohols. Mol. Pharmacol. 1984, 25, 249-255.
138. 3H-opiates to brain membranes. Life Sci 1983, 33, 725-733.
139. Tabakoff, B.; Hoffman, P.L. Alcohol interactions with brain opiate receptors. Life Sci. 1983, 32,197-204.
140. Levine, A.S.; Hess, S.H.; Morley, J.E. Alcohol and the opiate receptor. Alcohol. Cln. Exp. Res. 1983, 7, 83-84.
141. Hoffman, P.L.; Chung, C.T.; Tabakoff, B. Effects of ethanol, temperature, and endogenous regulatory factors on the characteristics of striatal opiate receptors. J. Neurochem. 1984, 43, 1003-1010
142. 5 enkephalin in mouse brain. Life Sci. 1983, 33, 2331-2337
143. Charness, M.E.; Gordon, A.S.; Diamond, I. Ethanol modulation of opiate receptors in cultured neural cells. Science 1983, 222, 1246-1248.
144. Tabakoff, B.; Urwyler, S.; Hoffman, P.L. Ethanol alters kinetic characteristics and function of striatal morphine receptors J. Neurochem. 1981, 37, 518-521.
145. Hoffman, P.L.; Urwyler, S.; Tabakoff, B. Alterations in opiate receptor function after chronic ethanol exposure. J. Pharmacol. Exp. Ther. 1982, 222,182-189.
146. Khatami, S.; Hoffman, P.L.; Shibuya, T.; Salefsky, B. Selective effect of ethanol on opiate receptor subtypes in brain. Neuropharmacology 1987, 26, 1503-1507.
147. Fadda, F.; Tronci, S.; Colombo, G.; Fratta, W. Diffrences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol. Clin. Exp. Res. 1999, 23, 1296-1305.
148. Turchan, J.; Przewlocka, B.; Toth, G.; Lason, W.; Borsodi, A.; Przewlocki, R. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 1999, 91, 971-977.
149. Altshuler, H.L.; Philips, P.E.; Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci. 1980, 26, 679-688.
150. Froehlich, J.C.; Harts, J.; Lumeng, L.; Li, T.-K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol. Biochem. Behav. 1990, 35, 385-390.
151. Froehlich, J.C.; Zweifel, M.; Harts, J.; Lumeng, L.; Li, T.-K.. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology 1991, 103, 467-472.
152. Hyytia, P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol. Biochem. Behav. 1993, 45, 697-701.
153. Sandi, C.; Borell, J.; Guaza, C. Involvement of kappa type opioids on ethanol drinking. Life Sci. 1988, 42, 1067-1075.
154. Spanagel, R.; Herz, A.; Shippenberg, T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J. Neurochem. 1990, 55, 1734-1740.
155. Spanagel, R., Herz, A.; Shippenberg, T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. USA 1992, 89, 2046-2050, 1992.
156. Spanagel, R. The influence of opioid antagonists on the discriminative stimulus of ethanol. Pharmacol. Biochem. Behav. 1996, 54, 645-649.
157. Myers, R.D.; Robinson, D.E.; mu and D2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats. Alcohol 1999, 18, 225-233.
158. Grisel, J.E.; Mogil, J.S.; Grahame, N.J.; Rubinstein, M.; Bellknap, J.K.; Crabbe, J.C. Low MJ. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression Brain Res. 1999, 835, 62-67.
159. Graham, N.J.; Low, M.J.; Cunningham, C.L. Intravenous self-administration of ethanol in β-endorphin-deficient mice. Alcohol. Clin. Exp. Res. 1998, 22, 1093-1098.
160. Hall, F.S.; Sora, L.; Li, X.-F.; Karmacharya, N.; Goodman, N.; Uhl, G.R. Decreased responses to ethanol in μ opiate receptor knockout mice . Soc. Neurosci. 1999, Abstract No 535,17, 25, 1327.
161. Volpicelli, J.R.; Alterman, A.I.; Hayashida, M.; O'Brien, C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992, 49, 876-880.
162. Jaffe, A.J.; Rounsaville, B.; Chang, G.; Shottenfeld, R.S.; Meyer, R.E.; O'Malley, S.S. Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient treatment matching. J. Consult. Clin. Psychol. 1996, 64, 1044-1053.
163. O'Malley, S.S. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol. 1996, 31 (Suppl 1), 77-81.
164. Gianoulakis, C.; Beliveau, D.; Angelogianni, P.; Meaney, M.; Thavundayil, J.; Tawar, V. Dumas, M. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 1989, 45, 1097-1109.
165. Gianoulakis, C.; Krishnan, B.; Thavundayil, J. Enhanced sensitivity of pituitary β-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry 1996, 5, 250-257.
166. Froehlich, J.C.; Zink, R.W.; Li, T.-K., Christian, J.C. Analysis of heritability of hormonal responses to alcohol in twins: Beta-endorphin as a potential biomarker of genetic risk for alcoholism. Alcohol. Clin. Exp. Res. 2000, 24, 265-277.
167. Genazzani, A.R.; Nappi, G.; Facchinetti, F. Central deficiency in beta-endorphin in alcohol addicts. J. Clin. Endocrin. Metab. 1982, 55, 583-586.
168. Vescovi, P.P.; Coiro, V.; Volpi, R.; Giannini, A.; Passeri, M. Plasma beta-endorphin but not met-enkephalin levels are abnormal in chronic alcoholics. Alcohol Alcohol. 1992, 27, 471-475.
169. Aguirre, J.C.; Del Arbol, J.L.; Rico, J.; Raya, J.; Miranda, M.T. Classification of alcoholics on the basis of plasma β-endorphin concentration. Alcohol 1995, 12,531-534.
170. Dai, X.; Thavundayil, J.; Gianoulakis, C. Differences in the responses of the pituitary β-endorphin and cardiovascular system to ethanol and stress as a function of family history. Alcohol. Clin. Exp. Res. 2002, 26, 1171-1180.
171. Dai, X.; Thavundayil, J.; Gianoulakis, C. Differences in the activity of the pituitary β-endorphin system as a function of chronic alcohol abuse and family history of alcoholism. Alcohol. Clin. Exp. Res. 2005, 29, 1965-1975.
172. Wand, G.S.; Mangold, D.; El Deiry, S.; McCaul, M.E.; Houver, D. Family history of alcoholism and hypothalamic opioidergic activity. Arch. Gen. Psychiatry 1998, 55, 1114-1119.
173. Kieffer, B.L.; Gaveriaux-Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 2002, 66, 285-306.
174. Sora, I.; Elmer, G.; Funada, M.; Pieper, J.; Li, X.F.; Hall, F.S.; Uhl, G.R. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001, 25, 41-54.
175. Delfs, J.M.; Kong, H.; Mestek, A. Chen, Y.; Yu, L.; Reisine, T.; Chesselet, M.F. Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J. Comp. Neurol. 1994, 345, 46-48.
176. Hoche, M.R.; Kople, K.; Wendel, B.; Rohde, K.; Flachmeier, C.; Kidd, K.K.; Berrettini, W.H.; Church, G.M. Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum. Mol. Genet. 2000, 9, 2895-2908.
177. Ikeda, K.; Ide, S.; Han, W.; Hayashida, M.; Uhl, G.R.; Sora, I. How individual sensitivity to opiates can be predicted by gene analysis. Trends Pharmacol. Sci. 2005, 26, 311-317.
178. Bergen, A.W.; Kokoszka, J.; Peterson,R.; Long, J.C.; Virkkunen, M.; Linnolla, M.; Goldman, D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 1997, 2, 490-494.
179. Bond, C.; LaForge, K.S.; Tian, M.; Melia, D.; Zhang, S.; Borg, L.; Gong, J.; Schluger, J.; Strong, J.A.; Leal, S.M.; Tischfield, J.A.; Kreek, M.J.; Yu, L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implication for opiate addiction. Proc. Natl. Acad. Sci. USA 1998, 95, 9608-9613.
180. Mestek, A.; Hurley, J.H.; Bye, L.S.; Campbell, A.D.; Chen, Y.; Tian, M. The human mu opioid rceptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci. 1995, 15, 2396-2406.
181. Befort, K.; Filliol, D.; Decaillot, F.M.; Gaveriaux-Ruff, C.; Hoehe, M.R.; Kieffer, B.L. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signalling J. Biol. Chem. 2001, 276, 3130-3137.
182. Beyer, A.W.; Koch, T.; Schroder, H.; Schulz, S.; Hollt, v. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 2004, 89, 553-560.
183. Wand, G.S.; McCaul, M.; Yang, X.; Reynolds, J.; Gotjen, d.; Lee, S.; Ali, A. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002, 26, 106-114.
184. Chong, R.Y.; Oswald, L.; Yang, X.; Uhart, M.; Lin, P.-I.; Wand, G.S. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006, 31, 204-211.
185. Ray, L.A.; Hutchison, K.E. A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in human. Alcohol. Clin. Exp. Res. 2004, 28, 1789-1795.
186. Oslin, D.W.; Berrettini, W.; Kranzler, H.R., Pettinati, H.; Volpicelli, J.R., O'Brien C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28, 1546-1552.
187. Oroszi, G.; Anton, R.F.; O'Malley S., Swift, R.; Pettinati, H.; Couper, D.; Yuan, Q.; Goldman, D. OPRM1 Asn40Asp predicts response to naltrexone treatment: A haplotype-based approach. Alcohol. Clin. Exp. Res. 2009, 33, 383-393.
188. Rassnick, S.; Stinus, L.; Koob, G.F. The effects of 6-hydroxydopamine lessions of the nucleus accumbens and the mesolimbic dopamine system on oral self-administration of ethanol in the rat. Brain Res. 1993, 623, 16-24.
189. Ikemoto, S.; McBride, W.J.; Murphy, J.M.; Lumeng, L.; Li, T.-K. 6-OHDA-lesions of the nucleus accumbens disrupt the acquisition but not maintenance of ethanol consumption in the alcohol-preferring P line of rats. Alcohol. Clin. Exp. Res. 1997, 21, 1042-1046.
190. Hodge, C.W.; Samson, H.H.; Chappelle, A.M. Alcohol self-administration: Further examination of the role of dopamine receptors in the nucleus accumbens. Alcohol. Clin. Exp. Res. 1997, 21, 1083-1091.
191. Jamensky, N.T.; Gianoulakis, C. Content of dynorphins and κ-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice Alcohol. Clin. Exp. Res. 1997, 21, 1455-1464.
192. De Vry,; Donselaar, I.; Van Ree, J.M. Food deprivation and acquisition of cocaine self-administration in rats: effect of naltrexone and haloperidol. J. Pharmacol. Exp. Ther. 1989, 251, 735-740.
193. Kuzmin, A.V.; Gerrits, M.A.F.M.; Van Ree, J.M.; Zvartau, E.E.; Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sci. 1997, 60, PL257-PL264.
194. Mello, N.K.; Negus, S.S. Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug selfadministration procedures. Neuropsychopharmacology 1996, 14, 375-424.
195. Ramsey, N.F.; Gerrits, M.A.F.M.; Van Ree, J.M. Naltrexone affects cocaine self-administration in naïve rats through the ventral tegmental area rather than dopaminergic target regions. Eur. Neuropsychopharmacol. 1999, 9, 93-99.
196. Reid, L.D.; Glick, S.D.; Menkens, K.A.; French, E.D.; Bilsky, E.J.; Porreca, F. Cocaine self-administration and naltrindole, a δ-selective opioid antagonist. Neuro Rep. 1995, 6, 1409-1412.
197. Glick, S.D.; Maisonneuve, I.M.; Raucci, J.; Archer, S. Kappa-opioid inhibition of morphine and cocaine self administration in rats. Brain Res. 1995, 681, 147-152.
198. Kuzmin, A.V.; Semenova, S.; Gerrits, M.A.F.M.; Svartau, E.E.; Van Ree, J.M. κ-Opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naïve rats and mice. Eur. J. Pharmacol. 1997, 321, 265-271.
199. Kosten, T.; Silverman, D.G.; Fleming, J.; Kosten, T.A.; Gawin, F.H.; Compton, M.; Jatlow, P.; Byck, R. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol. Psychiatry 1992, 32, 543-548.
200. Sweep, C.G.; Wiegant, V.M.; De Vry, J.; Van Ree, J.M. Beta-endorphin in brain limbic structures as a neurochemical correlate of psychic dependence on drugs. Life Sci. 1989, 44, 1133-1140.
201. Gerrits, M.A.F.M.; Wiegant, V.M.; Van Ree, J.M. Endogenous opioids implicated in the dynamics of experimental drug addiction: an in vivo autoradiographic analysis. Neuroscience 1999, 89, 1219-1227.
202. Sopori, M.L.; Savage, S.M.; Rattan, A.K.; Tejwani, G.A. Role of opioids in cigarette smoke-induced antinociception. Regul. Peptides 1994, (Suppl 1), S103-S104.
203. Dhatt, R.K.; Gudehithlu K.P.; Wemlinger, T.A.; Tejwani, G.A.; Neff, N.H.; Hadjiconstantinou, M. Proenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J. Neurochem. 1995, 64, 1878-1883.
204. Wewers, D.E.; Dhatt, R.K.; Snively, T.A.; Tejwani, G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkephalin levels in rats. Brain Res. 1999, 822, 117-123.
205. Del Arbol, J.L.; Raya Munoz, J.; Ojeda, L.; Lopez Cascales, A.; Rico Irles, J.; Miranda, M.T.; Ruiz Requena, M.E.; Aguire, J.C. Plasma concentrations of beta-endorphin in smokers who consume different numbers of cigarettes per day. Pharmacol. Biochem. Behav. 2000, 67, 25-28.
206. Wewers, M.E.; Dhatt, R.K.; Tejwani, G.A. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology 1998, 140, 185-190.
207. King, A.; Dingcai, C.; Vanier, C.; Wilcox, T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: Exploratory study. Alcohol. Clin. Exp. Res. 2009, 33, 1044-1050.
208. Melichar, J.K.; Daglish, M.R.C.; Nutt, D.J. Addiction and withdrawal-current views. Curr. Opin. Pharmacol. 2001, 1, 84-90
209. Strain, E.C.; Bigelow G.E.; Liebson , I.A.; Stitzer, M.L. Moderate vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999, 281, 1000-1005.
210. Pani, P.P.; Maremmani, I.; Pirastu, R. Tagliamonte, A.; Gassa, G.L. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000, 60, 39-50.
211. Jones, H.E.; Johnson, R.E.; Fudala, P.J.; Henningfield, J.E.; Heishman, S.J. Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans. Drug Alcohol Depend. 2000, 60, 29-37.
212. Miozzi, S.; Amato, L.; Vecchi, S., Davoli, M.; Kirchmayer, U.; Verster, A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst. Rev. 2006, 25(1), CD 001333.
213. Bell, J.; Byron, G.; Gibson, A.; Morris, A. A pilot study of buprenophrine-naltrexone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev. 2004, 23, 311-317.
214. Herz, A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997, 12, 99-111.
215. Myers, R.D.; Borg, S.; Mossberg, R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 1986, 3, 383-388
216. Kornet, M.; Goosen, C.; Van Ree, J.M. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology 1991, 104, 367-376.
217. Hubbell, C.L.; Mankes, R.F.; Reid, L.D. A small dose of morphine leads to drink more alcohol and achieve higher blood alcohol concentrations. Alcohol. Clin. Exp. Res. 1993, 17, 1040-1043
218. Krishnan-Sarin, S.; Jing, S.L.; Kurtz, D.L.; Zweifel, M. Portoghese, P.S.; Li, T.-K.; Froehlich, J.C. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology 1995, 120, 177-185.
219. Honkanen, A.;, Vilamo, L.; Wegelius, K.; Sarviharju, M.; Hyytia, P.; Korpi, E.R. Alcohol drinking is reduced by a mu(1)-but not by a delta-opioid receptor antagonist in alcohol-preferring rats. Eur. J. Pharmacol. 1996, 304, 7-13.
220. Davidson, D.; Amit, Z. Effects of naloxone on limited-access ethanol drinking in rats. Alcohol. Clin. Exp. Res. 1996, 20, 664-669.
221. Franck, J.; Lindholm, S.; Raaschou, P. Modulation of volitional ethanol intake in the rat by central δ-opioid receptors. Alcohol. Clin. Exp. Res. 1998, 22, 1185-1189.
222. Heyser, C.J.; Roberts, A.J.; Schulteis, G.; Koob, G.F. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol. Clin. Exp. Res. 1999, 23, 1468-1476.
223. Litten, R.Z.; Allen, J.; Ferting, J. Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol. Clin. Exp. Res. 1996, 20, 859-876.
224. Berg, B.J.; Pettinati, H.M.; Volpicelli, J.R. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf. 1996, 15, 274-282.
225. Volpicelli, J.R.; Volpicelli, L.A.; O'Brien, C.P. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol 1995, 30, 789-798.
226. Mason, B.J.; Ritvo, E.C.; Morgan, R.O.; Salvato, F.R.; Goldberg, G.; Welch, B.; Mantero-Atienza, E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCL for alcohol dependence. Alcohol. Clin. Exp. Res. 1994, 18, 1162-1167.
227. Drobes, D.J.; Anton, R.F.; Thomas, S.E.; Voronin, K. Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol. Clin. Exp. Res. 2004, 28, 1362-1370.
228. Karhuvaar, S.; Simojoki, K.; Virta, A.; Roberg, M.; Loyttyniemi, E.; Nurminem, T.; Kallio, A.; Makela, R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol. Clin. Exp. Res. 2007, 31, 1179-1187.
229. Cole, J.C.; Littleton, J.M.; Little, H.J. Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to plus-maze. Psychopharmacology 2000, 147, 403-411.
230. McCaul, M.E.; Wand, G.S.; Eissenberg, T.; Rohde, C.A.; Cheskin, L.J. Naltrexone alterss subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000, 22, 480-492.
231. Peterson, J.B.; Conrod, P.; Vassileva, J.; Gianoulakis, C.; Phil, R.O. Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol-intoxication. J. Psych. Neurosci. 2006, 31, 386-393.
232. Kranzler, H.R.; Modesto-Lowe, V.; Van Kirk, J. Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 2000, 22, 493-503.
233. Rezvani, A.H.; Overstreet, D.H.; Mason, G.A.; Janowsky, D.S.; Hamedi, M.; Clark, E. Jr.; Yang, Y. Combination pharmacotherapy: a mixture of small dose of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol. 2000, 35, 76-83.
234. Hoelter, S.M.; Spanagel, R. Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology 1999, 145, 360-369.
235. De Witte, P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict. Behav. 2004, 29, 1325-1339.
236. Littleton, J. Acamprosate in alcohol dependence: how does it work? Addiction 1995, 90, 1179-1188.
237. Mann, K.; Kiefer, F.; Spanagel, R.; Littleton, J. Acamprosate: recent findings and future research directions. Alcohol. Clin. Exp. Res. 2008, 32, 1105-1110.
238. Spanagel, R.; Kiefer, F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharm. Sci. 2008, 29, 109-115.
239. Kiefer, F.; Jahn, H.; Tarnaske, T.; Helwig, H.; Briken, P.; Holzbach, R.; Kampf, P.; Stracke, R.; Baer, M.; Naber, D.; Wiedemann, K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 2003, 60, 92-99.
240. Anton, R.F.; O'Maley, S.S; Ciraulo, D.A.; Couper, d.; Donovan, D.M.; Gastfriend, D.R.; Hosking, J.D.; Johnson, B.A.; LoCastro, J.S.; Longabaugh, R.; Mason, B.J.; Mattson, M.E.; Miller, W.R.; Pettinati, H.M.; Randall, C.L.; Swift, R.;Weiss, R.D.; Williams, L.D.; Zweben, A. COMBINE Study Research Group. Combined pharmacotherapies and behavioural interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295, 2003-2017.
241. Lesch, O.M.; Walter, H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol. 1996, 31 (Suppl 1): 63-67.
242. Anton, R.F. Neurobehavioral basis for the pharmacotherapy of alcoholism: current and future directions. Alcohol. Alcohol 1996, 31 (Suppl 1), 43-53.
243. Sperling, W.; Lesch, O.M. The reduction of alcohol consumption with novel pharmacological intervention. Eur. Psychiatry 1996, 11, 217-226.
244. Oslin, D.W.; Berrettini, W.; Kranzler, H.R.; Pettinati, H.; Gelernter, J.; Volpicelli, J.R.; O'Brien, C.P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003, 28, 1546-1552.
245. Anton, R.F.; Oroszi, G.; O'Maley, S.; Couper, D.; Swift, R.; Pettinati, H.; Goldman, D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. (COMBINE) study. Arch. Gen. Psychiatry 2008, 65, 135-144.